4TEEN4 Pharmaceuticals GmbH: Valuation, Funding & Investors
4TEEN4 Pharmaceuticals GmbH is focused on reversing life-threatening shock and restoring organ function with procizumab, a first-in-class antibody that blocks circulating DPP3, a key pathological driver of mortality in shock. The company is conducting a Phase 2a study to evaluate procizumab's potential as a treatment for shock caused by acute cardiovascular and septic events, aiming to improve survival in critically ill patients.
Leadership & Board
- Current Number of Employees
- 37
- Current LinkedIn Followers
- 2,228
Latest Estimated Valuation
- Total Amount Raised
- $55M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $55M
- Latest Funding Round
- Series C
Company Momentum Positive
4TEEN4 Pharmaceuticals GmbH LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
4TEEN4 Pharmaceuticals GmbH had 37 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
4TEEN4 Pharmaceuticals GmbH had 2,228 followers as of October 26, 2026. The number of followers increased by 10 (0.45%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 13, 2025 | Series C | $55.00M | ― |
Similar Companies
A snapshot of private companies similar to 4TEEN4 Pharmaceuticals GmbH, helping you discover and navigate related company profiles.
Related News and Analysis
